Data presented today show a reduction in treated spontaneous and traumatic bleeds and mean annualised bleeding rate (ABR) of 1.7 with concizumab[1]London, UK, 10 July 2022 – Novo Nordisk announced the phase 3 results of the explorer7 study, assessing the efficacy and safety of prophylactic treatment with conci.
Assisting court reporters with AI-enabled heuristics: What data journalists should know about building custom AI models cjr.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cjr.org Daily Mail and Mail on Sunday newspapers.